RenovoRx

During the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026, RenovoRx CEO, Shaun Bagai, will highlight progress in the pivotal Phase III TIGeR-PaC clinical trial, which is evaluating intra-arterial gemcitabine delivered via RenovoCath® in . Enrollment is expected to be completed by the end of June 2026 and final data anticipated in mid-to-late 2027. Learn more: https://bit.ly/4ertmCT

RenovoRx announced the publication of a peer-reviewed case study from researchers at Moffitt Cancer Center was recently published in Radiology Case Reports. The case study suggests the TAMP procedure with RenovoCath® may optimize delivery of intra-arterial gemcitabine directly near a tumor in a patient with , rather than through systemic IV administration. PET-CT imaging also showed a meaningful drop in tumor metabolic activity after treatment, suggesting PET may better monitor response following TAMP. Learn more: https://bit.ly/4owgpft

Fox News spotlighted RenovoRx's Trans-Arterial Micro-Perfusion (TAMP™) platform, which uses the RenovoCath® device to enable targeted delivery of therapy in difficult-to-treat tumors, like . TAMP is designed to localize therapy delivery while potentially reducing systemic exposure and improving patient outcomes. Read more: https://bit.ly/4dWwAix

RenovoCath is cleared by FDA for targeted delivery of chemotherapy to selected sites in the peripheral vascular system. The company is studying the use of RenovoCath-delivered gemcitabine for treatment of LAPC in an ongoing clinical trial study conducted under an IND.

New Cancer Tech Sends Chemo Straight To Tumors A targeted drug-delivery device may help some pancreatic cancer patients get chemotherapy with fewer body-wide side effects.

Our CEO, Shaun Bagai, will present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on Tuesday, June 23rd at 12:30 P.M. ET. Mr. Bagai will discuss RenovoRx’s record first quarter 2026 revenue, driven by growing demand for RenovoCath® as a standalone drug-delivery device. He will also highlight RenovoCath’s accelerating adoption at high-volume cancer centers and the expanding base of repeat orders. For details: https://bit.ly/4uSjNDT